2016 Jul 14;11(7):e0158779. doi: 10.1371/journal.pone.0158779.
Breuer A1, Haj CG1, Fogaça MV2, Gomes FV2, Silva NR2, Pedrazzi JF3, Del Bel EA4, Hallak JC3, Crippa JA3, Zuardi AW3, Mechoulam R1, Guimarães FS2.
Abstract
Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials the doses of CBD needed to achieve effects in anxiety and schizophrenia are high. We report now the synthesis of 3 fluorinated CBD derivatives, one of which, 4′-F-CBD (HUF-101) (1), is considerably more potent than CBD in behavioral assays in mice predictive of anxiolytic, antidepressant, antipsychotic and anti-compulsive activity. Similar to CBD, the anti-compulsive effects of HUF-101 depend on cannabinoid receptors.
- PMID: 27416026
- DOI: 10.1371/journal.pone.0158779